China Diabetes Drugs And Devices Market Size (2024 - 2029)

China Diabetes Drugs And Devices Market Analysis

The China Diabetes Drugs And Devices Market size is estimated at USD 19.66 billion in 2024, and is expected to reach USD 22.77 billion by 2029, growing at a CAGR of greater than 3.5% during the forecast period (2024-2029).

Diabetes affects about one out of every ten COVID-19 patients in China. Diabetes is linked to an increased risk of serious disease and death. The current study suggests that COVID-19 individuals with diabetes require focused early intervention. According to Peking University (Beijing, China), research, intensive care unit (ICU) patients had an approximately threefold higher prevalence of diabetes than non-ICU patients. Various studies on the prevalence of diabetes have diverse results.

During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, much greater than those without diabetes. Various studies on the prevalence of diabetes have diverse results. During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, which was much more significant than those without diabetes. Notably, respondents who reported medication shortages had a 63% higher rate of COVID-19 infection.

Type 1 diabetes patients will account for more than 9.5% of China's overall diabetes population in the current year. Blood glucose swings among insulin users are common in China owing to lifestyle and eating habits, and self-monitoring of blood glucose fails to adequately reflect the blood glucose profile since it only shows the glucose concentration at a single time point.

China has the highest number of diagnosed and undiagnosed diabetes cases in the world, as per Diabetes Research and Clinical Practice. The number of diagnosed diabetics in China has increased by 56% from 2011 to 2021. Over 75% of adults with diabetes reside in low- and middle-income countries. Diabetes-related health expenditures have surged by 316% to USD 966 billion globally over the past 15 years, with China ranking second with USD 165.3 billion.

Thus, a trend in the demand for diabetes drugs in China has been noted. In the pharmaceutical sector, insulin has a substantial market share. Insulin is used by around 100 million individuals worldwide, including all Type 1 diabetes patients and 10% to 25% of Type 2 diabetic patients. Insulin production is exceedingly complex, with just a few insulin manufacturers on the market. As a result, there is tremendous competition among these companies, which always seek to meet patient requests by offering the highest-quality insulin.

Thus, the above factors are expected to drive market growth over the forecast period.

China Diabetes Drugs And Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be injected several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. The Chinese diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring). The report offers value (in USD) and volume (in units) for the above segments.